Discovery Life Sciences and Mindpeak Team Up for Improved AI-Driven Cancer Biomarker Testing in Clinical Trials

Partnership for Precision in Cancer Research

In the evolving landscape of biomedical research, Discovery Life Sciences has forged a strategic alliance with Mindpeak, a recognized leader in AI-driven digital pathology. This partnership addresses a pressing issue in clinical trials: the inconsistency in biomarker interpretation among pathologists. This variability can negatively impact patient stratification and undermine crucial go/no-go decisions within drug development.

The Need for Change

Inconsistent interpretations can hinder the reliability of clinical trials, making it essential for biopharma companies to ensure accuracy in their trials. The integration of AI technology seeks to mitigate this problem, lending greater reliability to the process of biomarker analysis. The collaboration emphasizes enhancing biomarker quantification and improving inter-reader concordance, which are vital for aligning trial outcomes with patient needs.

A Synergistic Approach

The alliance will incorporate Mindpeak’s AI platform, which is designed to analyze immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) slides, into Discovery’s existing pathology services. By leveraging AI-enabled digital image analysis, the partnership seeks to enhance consistency in interpretation and provide vital insights for biopharma companies. Mindpeak’s advanced workflows will assist in safeguarding biopharma efforts by minimizing risks associated with biomarker development.

Greg Herrema, CEO of Discovery Life Sciences, noted, "As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modeling tools that can enable improved accuracy in biomarker analysis." This sentiment echoes the growing recognition of the need to fuse technology with clinical expertise to bolster the efficacy of therapeutic development.

Historical Background

Discovery Life Sciences has a rich history in the field of biospecimens and biomarker lab services. With over 15 years of experience, the company has trained more than 6,000 pathologists through its Biomarker Academy. Over the years, Discovery has supported more than 2,000 clinical trial programs, with 350 currently active. Notably, their efforts have culminated in over 35 IVDR-compliant studies involving various biomarkers across the European Union.

Meanwhile, Mindpeak, established in 2018, has been pioneering the integration of AI in digital pathology, focusing on enabling laboratories to extract actionable insights from tissue images. Their solutions span a range of applications, including subcellular biomarker quantification, predictive patient stratification, and more.

Future Directions

Through this partnership, the two companies aim to streamline trial processes and enhance data reproducibility within regulated environments, creating significant advantages for experimental therapeutics. Mindpeak’s Felix Faber emphasized that this collaboration will grant vital access to their AI tools and training, ultimately enhancing the precision and reliability of biomarker assessments in IHC and mIF applications.

The details of this collaboration will be further publicized at the upcoming AACR Annual Meeting 2026. Individuals interested in learning more about the tools and insights that emerge from this partnership can attend discussions at the Discovery Life Sciences exhibit from April 17-22 in San Diego, California.

In conclusion, the partnership between Discovery Life Sciences and Mindpeak represents a significant advancement in the field of cancer research. By combining clinical expertise with cutting-edge AI technology, both organizations are set to redefine the standards for cancer biomarker testing in clinical trials.